Repeated Favorable Responses to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in a Case of Advanced Lung Adenocarcinoma

Tuberculosis and Respiratory Diseases

article

Eun-Young Kim¹  Yoon-Hee Kim¹  Hee-Jung Ban¹  In-Jae Oh¹  Yong-Soo Kwon¹  Kyu-Sik Kim¹  Yu-Il Kim¹  Sung-Chul Lim¹  Young-Chul Kim¹ 

[1] Lung and Esophageal Cancer Clinic, Chonnam National University Hwasun Hospital

关键词: Adenocarcinoma;    Receptor;    Epidermal Growth Factor;    Gefitinib;   

DOI  :  10.4046/trd.2013.74.3.129

学科分类：医学（综合）

来源: The Korean Academy of Tuberculosis and Respiratory Diseases

【 摘 要 】

The presence of epidermal growth factor receptor ( EGFR ) mutation is a prognostic and predictive marker for EGFR-tyrosine kinase inhibitor (TKI) therapy. However, inevitably, relapse occurs due to the development of acquired resistance, such as T790M mutation. We report a case of repeated responses to EGFR-TKIs in a never-smoked woman with adenocarcinoma. After six cycles of gemcitabine and cisplatin, the patient was treated by gefitinib for 4 months until progression. Following the six cycles of third-line pemetrexed, gefitinib retreatment was initiated and continued with a partial response for 6 months. After progression, she was recruited for an irreversible EGFR inhibitor trial, and the time to progression was 11 months. Although EGFR direct sequencing on the initial diagnostic specimen revealed a wild-type, we performed a rebiopsy from the progressed subcarinal node at the end of the trial. The result of peptide nucleic acid clamping showed L858R/L861Q.

【 授权许可】

CC BY-NC